CA2791190C - Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and use thereof - Google Patents

Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and use thereof Download PDF

Info

Publication number
CA2791190C
CA2791190C CA2791190A CA2791190A CA2791190C CA 2791190 C CA2791190 C CA 2791190C CA 2791190 A CA2791190 A CA 2791190A CA 2791190 A CA2791190 A CA 2791190A CA 2791190 C CA2791190 C CA 2791190C
Authority
CA
Canada
Prior art keywords
levofloxacin
genus
ophthalmic solution
ocular infection
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2791190A
Other languages
English (en)
French (fr)
Other versions
CA2791190A1 (en
Inventor
Takashi Nagano
Koji Sakanaka
Masatsugu Nakamura
Kouichi Kawazu
Hajime Ibuki
Kayoko Sakamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd, Daiichi Sankyo Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of CA2791190A1 publication Critical patent/CA2791190A1/en
Application granted granted Critical
Publication of CA2791190C publication Critical patent/CA2791190C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2791190A 2010-02-25 2010-12-16 Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and use thereof Expired - Fee Related CA2791190C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010-040281 2010-02-25
JP2010040281 2010-02-25
PCT/JP2010/072685 WO2011104981A1 (ja) 2010-02-25 2010-12-16 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤、眼感染症の治療方法、レボフロキサシンもしくはその塩またはそれらの溶媒和物、ならびにその使用

Publications (2)

Publication Number Publication Date
CA2791190A1 CA2791190A1 (en) 2011-09-01
CA2791190C true CA2791190C (en) 2017-12-12

Family

ID=44506417

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2791190A Expired - Fee Related CA2791190C (en) 2010-02-25 2010-12-16 Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and use thereof

Country Status (16)

Country Link
US (1) US20120316158A1 (https=)
EP (1) EP2540299B1 (https=)
JP (3) JP5600056B2 (https=)
KR (2) KR20130043611A (https=)
CN (1) CN102770141A (https=)
BR (1) BR112012021247A2 (https=)
CA (1) CA2791190C (https=)
EA (1) EA201290827A1 (https=)
ES (1) ES2568647T3 (https=)
MX (1) MX349603B (https=)
MY (1) MY183483A (https=)
NZ (1) NZ602126A (https=)
PH (2) PH12012501674A1 (https=)
SG (1) SG183427A1 (https=)
TW (1) TWI488627B (https=)
WO (1) WO2011104981A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130043611A (ko) * 2010-02-25 2013-04-30 다이이찌 산쿄 가부시키가이샤 레보플록사신 또는 그의 염 또는 그들의 용매화물을 함유하는 안감염증 치료용 점안제, 안감염증의 치료 방법, 레보플록사신 또는 그의 염 또는 그들의 용매화물, 및 그의 용도
CN103550144B (zh) * 2013-10-25 2015-10-14 深圳朗欧医药集团有限公司 盐酸左氧氟沙星组合物注射液及其制备方法
JP6363833B2 (ja) * 2013-11-22 2018-07-25 ナノシータ株式会社 薄膜状高分子構造体
CN104606198A (zh) * 2015-01-09 2015-05-13 周元铎 盐酸左氧氟沙星在制备防治家蚕细菌性败血病药中的应用
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3038722B2 (ja) 1989-06-23 2000-05-08 日本電気株式会社 接合型電界効果トランジスタ
JP3192290B2 (ja) 1993-08-04 2001-07-23 カネボウ株式会社 ポリエステル製耐熱ボトル
US7629458B2 (en) * 2001-10-03 2009-12-08 Teva Pharmaceutical Industries Ltd. Preparation of levofloxacin and hemihydrate thereof
ES2292844T3 (es) * 2001-11-30 2008-03-16 Lg Life Sciences Ltd. Utilizacion de gemifloxacina o sus sales con un antibiotico b-lactamico para la preparacion de medicamentos.
US20050009836A1 (en) * 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
WO2005000307A1 (en) * 2003-06-26 2005-01-06 Santen Pharmaceutical Co., Ltd. Ophthalmic composition containing quinolones and method of use
MX2008010222A (es) * 2006-02-10 2008-10-17 Pari Pharma Gmbh Antibioticos nebulizados para terapia de inhalacion.
WO2008005276A2 (en) * 2006-06-30 2008-01-10 Directcontact Llc Growth factor delivery system containing antimicrobial agents
EP2143422A1 (en) * 2008-07-11 2010-01-13 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections
KR20130043611A (ko) * 2010-02-25 2013-04-30 다이이찌 산쿄 가부시키가이샤 레보플록사신 또는 그의 염 또는 그들의 용매화물을 함유하는 안감염증 치료용 점안제, 안감염증의 치료 방법, 레보플록사신 또는 그의 염 또는 그들의 용매화물, 및 그의 용도

Also Published As

Publication number Publication date
EA201290827A1 (ru) 2013-03-29
TWI488627B (zh) 2015-06-21
KR20130043611A (ko) 2013-04-30
BR112012021247A2 (pt) 2018-04-03
EP2540299B1 (en) 2016-04-13
ES2568647T3 (es) 2016-05-03
SG183427A1 (en) 2012-09-27
PH12016501747B1 (en) 2022-06-22
KR20170070265A (ko) 2017-06-21
JP5600056B2 (ja) 2014-10-01
TW201129364A (en) 2011-09-01
JP2011195564A (ja) 2011-10-06
US20120316158A1 (en) 2012-12-13
EP2540299A4 (en) 2013-07-24
JP5674882B2 (ja) 2015-02-25
JP2012162532A (ja) 2012-08-30
MX2012009844A (es) 2012-09-21
PH12016501747A1 (en) 2019-02-11
MY183483A (en) 2021-02-20
AU2010346703A1 (en) 2012-09-20
NZ602126A (en) 2013-10-25
HK1177887A1 (en) 2013-08-30
MX349603B (es) 2017-08-03
JP2013241464A (ja) 2013-12-05
EP2540299A1 (en) 2013-01-02
PH12012501674A1 (en) 2012-11-05
CA2791190A1 (en) 2011-09-01
CN102770141A (zh) 2012-11-07
WO2011104981A1 (ja) 2011-09-01

Similar Documents

Publication Publication Date Title
US20110294768A1 (en) Ophthalmic Suspension for Ocular Use
CA2791190C (en) Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and use thereof
MX2014011468A (es) Gotas para los ojos que contienen diquafosol.
Mah et al. Besifloxacin: efficacy and safety in treatment and prevention of ocular bacterial infections
WO2016072440A1 (ja) 眼科用水性組成物
O’Brien Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis
Romanowski et al. Cefiderocol is an effective topical monotherapy for experimental extensively drug-resistant Pseudomonas aeruginosa keratitis
Tabbara et al. Treatment of acute bacterial conjunctivitis with topical lomefloxacin 0.3% compared to topical ofloxacin 0.3%
HK1177887B (en) Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof
WO2016196989A1 (en) Topical composition
US11672798B2 (en) Ciprofloxacin ophthalmic topical composition for treating ocular disease
Tabbara et al. Effects of fusidic acid on staphylococcal keratitis.
AKANDA et al. Efficacy of Perioperative Oral Antibiotics in the Prevention of Acute Infective Endophthalmitis after SICS
HK1178045A (en) Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof
Adamiec-Mroczek et al. Efficient antiseptic prophylaxis in the era of antibiotic resistance
WO2024105689A1 (en) Novel ophthalmic composition
WO2018169967A1 (en) Acorafloxacin in treating ocular infections
Stevens et al. Fluoroquinolones for the treatment of microbial infections
CN101385728A (zh) 一种巴洛沙星或其盐的滴眼液制剂及其制备方法
Sanfilippo Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections
Hariprasad et al. of Endophthalmitis
Hariprasad et al. Evidence-Based Medicine: The Prophylaxis and Treatment of Endophthalmitis
Wittpenn Considerations in the Treatment of Ocular Inflammation: V. Infectious Conjunctivitis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150625

MKLA Lapsed

Effective date: 20211216